Celyad Oncology SA
XBRU:CYAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Celyad Oncology SA
XBRU:CYAD
|
BE |
|
H
|
Hammerson PLC
OTC:HMSNF
|
UK |
|
Enova International Inc
NYSE:ENVA
|
US |
|
A
|
Achyut Healthcare Ltd
BSE:543499
|
IN |
|
S
|
Shop Apotheke Europe NV
XETRA:SAE
|
NL |
|
Greek Organisation of Football Prognostics SA
OTC:GRKZF
|
GR |
|
S
|
Shandong Boan Biotechnology Co Ltd
HKEX:6955
|
CN |
|
Tanvi Foods (India) Ltd
BSE:540332
|
IN |
|
C
|
China Resources Beverage Holdings Co Ltd
HKEX:2460
|
CN |
|
B
|
Bharat Wire Ropes Ltd
NSE:BHARATWIRE
|
IN |
|
PSI Software AG
XETRA:PSAN
|
DE |
|
9
|
99 Speed Mart Retail Holdings Bhd
KLSE:99SMART
|
MY |
|
CK Hutchison Holdings Ltd
OTC:CKHUF
|
HK |
|
D
|
DTXS Silk Road Investment Holdings Co Ltd
HKEX:620
|
HK |
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
CN |
|
N
|
NEC Networks & System Integration Corp
TSE:1973
|
JP |
|
C
|
Clearway Energy Inc
NYSE:CWEN
|
US |
Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
